AcquiredStartups
Home/North America/Healthtech & bio
Acquisition · Healthtech & bio · United States

Dechra buys Gallant to add off-the-shelf stem-cell therapies for pets

The EQT-owned veterinary drugmaker closed the deal a week after agreeing it, taking on a San Diego biotech whose first product is expected as early as 2027.

ASAcquired deals deskNorth America9 November 2026 · 3 min read
Dechra acquires Gallant
Image: Dechra (press release)

Dechra, a veterinary pharmaceuticals group owned by funds managed by private equity firm EQT, has bought Gallant Pet, Inc., a San Diego biotech that develops ready-to-use stem-cell therapies for pets. Dechra said in a statement dated November 9, 2026 that it had signed an agreement to acquire the company, and the deal was reported on November 10. It announced on November 17 that the purchase was complete.

The two sides agreed to keep the terms confidential, and no price was disclosed.

Gallant is now part of Dechra. Its chief executive, Dr. Linda Black, said the team would carry on its work as part of Dechra.

What Gallant built

Gallant works on mesenchymal stromal cell (MSC) therapies, a type of cell treatment used in regenerative medicine. Its products are designed to be supplied off the shelf, ready for a veterinarian to use, and are given as an intravenous injection, according to the company's website. Gallant says the cells can help rebalance the immune system, reduce inflammation and support tissue repair.

The company's website lists five conditions in its pipeline: chronic gingivostomatitis, osteoarthritis and chronic kidney disease in cats, and osteoarthritis and atopic dermatitis in dogs. Gallant says each therapy is going through the US Food and Drug Administration's review and approval process, and its therapies remain investigational. Dechra said the first product from the pipeline could arrive as early as 2027.

Gallant's news page lists announcements of positive pilot data in feline and canine osteoarthritis, eligibility for an expanded FDA conditional approval pathway, and a distribution partnership with MWI Animal Health for an expected conditionally approved MSC therapy. Gallant has a manufacturing facility in San Diego, Dealroom reported.

“Gallant was built on a bold idea that we could make regenerative medicine accessible for all pets in need. Dechra understood that vision from the start. We are thrilled to begin this new chapter as part of Dechra who shares our dedication to science and heart.”Dr. Linda Black, CEO, Gallant
Funding historyTotal raised n/a
2025Series BDigitalis Ventures$18m

Why Dechra is buying

Dechra said the deal fits a long-term strategy of serving unmet needs in specialty veterinary care, and that it takes the company into regenerative medicine as a new therapeutic platform. It said Gallant's work could widen the options vets have for chronic and complex conditions.

Dechra called the deal another milestone in what it described as its transformation, and said Gallant's pipeline could help make regenerative medicine a valued standard in veterinary practice. In its November 9 statement, it described Gallant as a recognised leader in regenerative medicine and the deal as complementary to its existing business.

Dr. Cathy Knupp, Dechra's chief scientific officer, said the company would combine its specialty animal health expertise, global reach and relationships with veterinarians with Gallant's science and regenerative medicine platform. Black said Dechra had understood Gallant's aim of making regenerative medicine available to all pets that need it from the start.

The team and the funding

Black joined Gallant as a founding team member in 2019 and became chief executive in April 2021 after serving as president and chief scientific officer, according to the company's website. She previously ran product development at VetStem Biopharma, an earlier veterinary stem cell company, and was president and chief scientific officer of Medicus Biosciences from 2016 to 2019.

Gallant raised an $18 million Series B round in June 2025, led by Digitalis Ventures, according to Dealroom. Dealroom's company data shows a different total raised figure, and the full list of Gallant's investors was not reported, so its total funding is not clear.

Neither company said how many people Gallant employs.

Dechra's owners and recent deals

Dechra has been owned since January 2024 by funds managed by EQT, alongside the Abu Dhabi Investment Authority, Investors in Healthcare reported. In July 2024 it bought US-based Invetx for $520 million.

Dechra announced the completion of the Gallant deal from Boston, where it has set up its global headquarters. The company describes itself as a global leader in veterinary specialty care.

Dechra says it serves veterinary professionals, pet owners and horse owners with medicines and related products, and that it works through partnerships with veterinarians. Gallant's therapies would add a cell-based option to that range if they are approved.

Neither company said what regulatory steps remain before Gallant's first therapy can be sold, or whether Gallant will keep its own brand.

Sources